Navigation Links
Baxter Announces Licensing Agreement for Innocoll's Gentamicin Surgical Implant in the United States
Date:8/25/2008

ietary collagen-based technologies, CollaRx(R) and Liquicoll(R). Innocoll's lead product, Gentamicin Surgical Implant for the treatment and prevention of SSIs, is approved for sale in 49 countries in Europe, Latin America, the Middle East, Africa and Asia. The gentamicin surgical implant is currently in Phase III development in the United States for the prevention of SSIs. Other late stage pharmaceutical products in Innocoll's development pipeline include CollaRx Gentamicin Topical for the treatment and prevention of infected diabetic foot ulcers and CollaRx Bupivacaine Implant for the management of post-operative pain, both of which are currently in Phase II development. For more information, please visit http://www.innocollinc.com.

About Baxter

Baxter Healthcare Corporation is the principal U.S. operating subsidiary of Baxter International Inc. (NYSE: BAX). Baxter International Inc. develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

This release includes forward-looking statements regarding Baxter's expectations related to its licensing agreement with Innocoll and the timing of U.S. regulatory approval of Innocoll's gentamicin surgical implant. These statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from thos
'/>"/>

SOURCE Baxter Healthcare Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Baxter Declares Quarterly Dividend
2. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
3. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
4. Baxters Board of Directors Declares Quarterly Dividend
5. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
6. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
7. Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
8. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
9. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
10. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
11. Baxter Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... NEW YORK , Oct. 24, ... formerly Access Pharmaceuticals, Inc. (ACCP), a biopharmaceutical company ... has implemented a 1-for-50 reverse split of its ... on Friday, October 24, 2014. PlasmaTech,s common stock ... CUSIP number 72754H109 and temporary ticker symbol "ACCPD". ...
(Date:10/22/2014)... , Oct. 22, 2014 New test innovations ... in vitro diagnostic (IVD) test industry, especially as companies ... market researcher listed more than 25 testing innovations in ... the future of IVD products. Kalorama details the new approaches ... Worldwide Market for In Vitro Diagnostic Tests , ...
(Date:10/22/2014)... Md. (PRWEB) October 21, 2014 Shimadzu ... an LC/MS/MS data tool for the pain management and ... of data processing and review by allowing users to ... to clinicians. , QuantAnalytics allows analysts to filter ... This expedites data processing by eliminating the need to ...
(Date:10/22/2014)... Rock Hill, SC (PRWEB) October 22, 2014 ... the expansion of its cardiovascular pharmacogenetics menu, which ... improved patient outcomes. With PCLS’s evidence-based results, ... individual needs and optimize their therapy, while minimizing ... , In the U.S., according to the FDA ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3
... Cause of ... Death, Yearly, Liver Cancer Alone ... Growing; Viral Hepatitis Declines, MILAN, April 23 More than 6,000 physicians ... the opening sessions of the 43rd Annual Meeting of the,European Association for the ...
... image are better than one for analyzing tumors , ... determine the amount of oxygen in a tumor very useful, because ... a poor outcome. A new method to do this and to ... been developed and used to image tumors in mice by Murali ...
... Some of the biggest-selling,biologics developed during the boom years ... and insulin, have lost patent,protection in the U.S. in ... $40 billion. This opens up a huge potential market ... a new report by Kalorama,Information, Biogenerics: the World Market ...
Cached Biology Technology:Liver Diseases: A Huge European Health Burden, But Some Trends are Positive 2Liver Diseases: A Huge European Health Burden, But Some Trends are Positive 3JCI table of contents: April 22, 2008 2JCI table of contents: April 22, 2008 3JCI table of contents: April 22, 2008 4JCI table of contents: April 22, 2008 5JCI table of contents: April 22, 2008 6JCI table of contents: April 22, 2008 7JCI table of contents: April 22, 2008 8JCI table of contents: April 22, 2008 9JCI table of contents: April 22, 2008 10JCI table of contents: April 22, 2008 11JCI table of contents: April 22, 2008 12Huge Potential in Biosimilars if Generic Providers Overcome Regulatory Hurdles 2
(Date:10/14/2014)... in Cancer Research shows SIRT6—a protein known ... promote the development of skin cancers by turning on ... sun-damaged skin cells. , Previously considered protective, SIRT6 is ... that help regulate genomic stability and prevent some of ... DNA damage, which can lead to cancer. This study, ...
(Date:10/14/2014)... N.Y. – Scientists have sequenced the house fly genome ... one might expect from an insect that thrives in ... published Oct. 14 in the journal Genome Biology ... biology and of how flies quickly adapt to resist ... Adult house flies (Musca domestica) carry and transmit more ...
(Date:10/14/2014)... new kind of stem cell that can become either a ... according to a study published today in the journal ... type contradicts current theory on how organs arise from cell ... of, and future treatment for, liver cancer., Thanks to stem ... being made up of more than 200 cell types. The ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2House fly genome reveals expanded immune system 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
... provide a look at the ash and gas clouds being ... NOAA,s GOES-13 satellite to provide a week long look at ... westerly winds carry the debris (ash and smoke) far to ... down the ash before it can go far in the ...
... 2012 Scientists at The Scripps Research Institute have ... the market to treat neuropathic pain and epilepsy, helps ... treatments, gabapentin targets stress systems in the brain that ... 12-week trial of 50 treatment-seeking cannabis users, those who ...
... /PRNewswire-iReach/  -- Global Information Inc. is announces limited time ... important Boston healthcare conferences: Next-Gen Kinase ... rapidly maturing kinase inhibitors field will gather to explore ... Next-Gen Kinase Inhibitors Conference in Cambridge, MA. ...
Cached Biology News:NASA's new satellite movie of 1 week's ash activity from Mexico's Popocatepetl Volcano 2Scripps research scientists find anticonvulsant drug helps marijuana smokers kick the habit 2Scripps research scientists find anticonvulsant drug helps marijuana smokers kick the habit 3Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 2Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 3
Economical and manually filled LN2 vacuum insulated storage container offers high capacity and low nitrogen consumption while offering convenient storage of samples....
... DNase I Amplification Grade ... DNA to oligodeoxyribonucleotides. The ... units/mg. DNAse I Amplification ... and tested for absence ...
... of Cell Cultures (ECACC) in conjunction with ... West of England, Bristol, UK, have produced ... of HER2, oestrogen and progresterone receptor assays. ... of formalin fixed, breast cancer cell lines; ...
... 3C protease from human rhinovirus (HRV 3C) ... brand line of restriction grade proteases. The ... 6XHis-fusion protein, which recognizes the same cleavage ... small, 22 KDa size of the protease, ...
Biology Products: